Nonfamilial Pseudoxanthoma Elasticum: A Case Report With Review of Selected Literature Authors: Emilio Peniche‐Luna, Karen Uriarte‐Ruiz, José Eduardo Pérez‐Nieto, Genaro Briseño‐Gascón, María Elisa Vega‐Memije, Simón Guzmán‐Bucio Published: 2026 ABSTRACT ABSTRACTA 44‐year‐old woman with classic cutaneous manifestations of nonfamilial PXE presented with multiple 3 to 10 mm yellowish papules coalescing into well‐demarcated, cobblestone‐like plaques. Previous ophthalmologic evaluation revealed retinal angioid streaks, while no cardiovascular involvement was reported. PXE is a rare multisystem disorder associated with significant morbidity, requiring a multidisciplinary approach to optimize patient outcomes and quality of life. Cutaneous involvement usually represents the initial manifestation of the disease; therefore, accurate recognition of these lesions may facilitate prompt diagnosis and prevent further complications. Advances in the understanding of the underlying molecular pathways open the possibility for the development of novel therapeutic strategies, which may improve patient prognosis and potentially modify the natural history of the disease. Introduction Pseudoxanthoma elasticum (PXE) is a rare autosomal recessive genetic disorder with an estimated global prevalence of 1:25,000 to 1:100,000, slight female predominance (2:1) and no major racial or ethnic predilection [1]. PXE is caused by mutations in the ABCC6 gene on chromosome 16p13.1, which encodes MRP6, a transmembrane protein involved in tissue mineralization homeostasis [2]. These mutations result in dystrophic calcification of elastic tissues, primarily affecting the skin, eyes and cardiovascular system. The earliest manifestations of PXE typically arise in the skin during the second to third decade of life, with the appearance of small, isolated yellowish papules that coalesce into reticulated plaques on flexural areas, giving a cobblestone‐like appearance [3]. In some cases, mucosae may be involved. Ocular and vascular involvement develop at final stages [4, 5]. Diagnosis of PXE is based on a combination of clinical and histopathological criteria (Table 1) [6]. In the absence of curative or disease modifying therapies, management is multidisciplinary and focuses on surveillance and treatment of related complications [7]. We describe the case of a patient presenting with nonfamilial PXE with classical manifestations on the skin, emphasizing the significance of clinical and histopathological examination in the differential diagnosis, with an insight of the current and emerging therapeutic options which may improve patient prognosis and potentially modify the natural history of the disease. TABLE 1Major and minor clinical criteria for establishing the diagnosis of PXE. Major criteria Skin manifestationsOcular manifestationsProven genetic mutation of both alleles Skin Yellowish papules and/or plaques on the neck or flexural areasFragmentation, clumping, and/or calcification of elastic fibers in a skin biopsy taken from clinically affected skin 2 Eye Peau d'orange changes in the retinaAngioid streaks > 1 disc in diameter 3 Genetics Mutation in both alleles of the ABCC6 geneFirst‐degree relative with a definitive diagnosis of PXE Minor criteria Early ocular changesProven genetic mutation of a single allele Eye Angioid streaks < 1 disc in diameterComet or wing sign in the retina Genetics Mutation in one allele of the ABCC6 gene Note: Definitive diagnosis: two or more major criteria from different categories. Probable diagnosis: two or more criteria from the same category or one major and one minor criterion from different categories. Possible diagnosis: one major criterion or two or more minor criteria. Major and minor clinical criteria for establishing the diagnosis of PXE. Skin manifestations Skin manifestations Ocular manifestations Ocular manifestations Proven genetic mutation of both alleles Proven genetic mutation of both alleles Skin Skin Yellowish papules and/or plaques on the neck or flexural areas Yellowish papules and/or plaques on the neck or flexural areas Fragmentation, clumping, and/or calcification of elastic fibers in a skin biopsy taken from clinically affected skin Fragmentation, clumping, and/or calcification of elastic fibers in a skin biopsy taken from clinically affected skin 2 Eye Peau d'orange changes in the retinaAngioid streaks > 1 disc in diameter Eye Peau d'orange changes in the retinaAngioid streaks > 1 disc in diameter Peau d'orange changes in the retina Peau d'orange changes in the retina Angioid streaks > 1 disc in diameter Angioid streaks > 1 disc in diameter 3 Genetics Mutation in both alleles of the ABCC6 geneFirst‐degree relative with a definitive diagnosis of PXE Genetics Mutation in both alleles of the ABCC6 geneFirst‐degree relative with a definitive diagnosis of PXE Mutation in both alleles of the ABCC6 gene Mutation in both alleles of the ABCC6 gene First‐degree relative with a definitive diagnosis of PXE First‐degree relative with a definitive diagnosis of PXE Early ocular changes Early ocular changes Proven genetic mutation of a single allele Proven genetic mutation of a single allele Eye Angioid streaks < 1 disc in diameterComet or wing sign in the retina Eye Angioid streaks < 1 disc in diameterComet or wing sign in the retina Angioid streaks < 1 disc in diameter Angioid streaks < 1 disc in diameter Comet or wing sign in the retina Comet or wing sign in the retina Genetics Mutation in one allele of the ABCC6 gene Genetics Mutation in one allele of the ABCC6 gene Mutation in one allele of the ABCC6 gene Mutation in one allele of the ABCC6 gene Note: Definitive diagnosis: two or more major criteria from different categories. Probable diagnosis: two or more criteria from the same category or one major and one minor criterion from different categories. Possible diagnosis: one major criterion or two or more minor criteria. Case History/ Examination A 44‐year‐old woman presented to our outpatient clinic for dermatologic evaluation with classic cutaneous manifestations of PXE. Two years prior to presentation, she had undergone ophthalmologic evaluation at an external hospital (National Institute of Rehabilitation, Mexico City) due to decreased visual acuity, which revealed the presence of angioid streaks. Following this finding, she was referred to our hospital for evaluation. Differential Diagnosis, Investigations and Treatment Dermatologic examination showed multiple 3–10 mm yellowish papules coalescing into well demarcated, cobblestone‐like plaques (Figure 1) involving the trunk, axillae (Figure 2), anterior neck (Figure 3a), groin (Figure 3b), and bilateral flanks. According to the patient's medical history, the lesions had first appeared 20 years earlier and had progressively increased in number and size over time. Upon direct questioning, the patient denied additional symptoms or prior treatments. She reported no relatives with similar symptoms. Significant family history included systemic arterial hypertension in both parents and a brother, as well as a mother with type 2 diabetes; she reported having three healthy children. Cobblestone‐like plaques on dermoscopy with a yellowish color, smooth surface, and well‐defined borders. The presence of yellowish papules is observed in both axillary folds, which coalesce, giving the affected skin a loose, cobblestone appearance. Lesions affecting the anterior neck and inguinal fold, respectively. Given the suspected diagnosis of PXE, the case was presented to the Dermatologic Surgery service for a skin biopsy after written informed consent, followed by histopathological examination. The biopsy revealed no epidermal changes. In the middle reticular dermis, granulated basophilic material was observed, arranged in a linear and nodular pattern, in different directions between the collagen bundles (Figure 4). Elastic fiber staining revealed irregular, thickened, fragmented, granular, and randomly arranged fibers, compatible with elastorrhexis (Figure 5). Von Kossa staining was positive, revealing small, granular calcium deposits attached to the elastic fibers (Figure 6). A mid‐reticular distribution of elastorrhexis, along with a positive von Kossa staining, allowed exclusion of PXE‐like papillary dermal elastolysis (PXE‐PDE) as a differential, typically confined to the superficial dermis and lacking calcification, thereby confirming the diagnosis of PXE. Granulated basophilic material in the mid‐reticular dermis. Elastic fiber staining showing elastorrhexis. Von Kossa staining showing granular calcium deposits attached to elastic fibers. Conclusion and Results (Outcome and Follow‐Up) Although she manifested no cardiovascular symptoms at the time of our consultation, she was internally referred within our hospital to the Cardiology Department for baseline evaluation given the association with cardiovascular manifestations. No genetic testing was performed at our clinic; however, she was also internally referred to Genetics for further counseling and for outreach to family members. Preventive measures were given regarding the use of over‐the‐counter drugs. Due to the ocular involvement, the patient will continue to be externally monitored at the National Institute of Rehabilitation, pending optical coherence tomography (OCT) to assess the extent of ocular involvement. Discussion Our patient presented with classic cutaneous manifestations of PXE, with skin involvement representing the initial sign of disease. Mucosal involvement may also occur, most frequently affecting the labial mucosa [3, 4, 8]. In our case, mucosal evaluation revealed tortuous vessels and discoloration of the labial mucosa under 120× magnification (Figure 7), findings that further support the spectrum of mucocutaneous involvement described in PXE. Given this, it is important to recognize that PXE remains a rare disorder, with relatively few cases reported in the literature [9]. Despite its rarity, PXE is considered the prototype disease of ectopic mineralization [10], where clinical evaluation plays a central role in raising diagnostic suspicion, as the skin represents the most accessible site for initial assessment. Systematic evaluation revealed tortuous vessels and involvement of the oral mucosa, visible at 120× magnification. Dermoscopy may aid in excluding atypical or PXE‐like conditions [11]. The most characteristic dermoscopic pattern of PXE consists of coalescent and reticulated clusters, with multiple irregular, linearly arranged yellowish‐white areas alternating with linear vessels on a reddish background [12]. Histopathological examination is essential for establishing the diagnosis, with elastorrhexis representing the hallmark feature along with a positive von Kossa staining. In atypical or inconclusive cases, pathogenic ABCC6 mutations can confirm the diagnosis [9, 13]. Due to its multiple metabolic pathways, PXE is a multisystemic disorder. Ocular involvement can cause hemorrhage, scarring, metamorphopsia, and eventual vision loss [14]. Cardiovascular manifestations include peripheral arterial disease, premature atherosclerosis, and accelerated vascular calcification, which represent a major source of morbidity in PXE and warrant an early referral to Cardiology or Vascular Medicine. Gastrointestinal involvement, although less common, may include gastrointestinal bleeding and should be considered when evaluating anemia or when selecting antithrombotic therapies [2, 3, 4]. Management of PXE remains supportive and preventive, focusing on annual surveillance, cardiovascular risk reduction, and patient education. The use of statins along with moderate physical activity is recommended to reduce the risk of atherosclerosis and vascular calcification [7, 15]. Genetic counseling is essential to assess the risk of recurrence, where absence of similar symptoms in relatives might be explained by the phenomenon of variable expressivity [16]. Contact sports should be avoided due to the high risk of retinal hemorrhage, and antithrombotic therapy should be individualized, balancing hemorrhagic risk with cardiovascular indications, particularly in patients with established peripheral arterial disease. Skin lesions, provided there are no contraindications, may be removed through surgical intervention. Emerging therapies targeting ectopic calcification pathways remain investigational. In recent years, clinical trials have demonstrated potential benefits from a high‐magnesium diet [17, 18]. Nollet et al. have proposed the possibility of new therapeutic strategies combating the DDR/PARP1 pathway through the pleiotropic effects of agents such as minocycline [19]. Shimada et al. reported the potential use of phosphate and pyrophosphate analogues in reducing disease progression [20, 21]. Additionally, Rose et al. described clinical improvement associated with magnesium oxide supplementation [18]. Nevertheless, further studies are required to establish efficacy and long‐term safety of emerging therapies. We emphasize the importance of recognizing PXE as a rare condition that can cause significant morbidity, highlighting the need for a multidisciplinary approach to optimize patient quality of life. Cutaneous involvement usually represents the initial manifestation of the disease; therefore, accurate recognition of these lesions can facilitate prompt diagnosis. Mucocutaneous involvement can be useful in asymptomatic or atypical cutaneous manifestations. Ocular involvement should be closely monitored, as it can lead to visual impairment, and cardiovascular involvement should be carefully assessed to prevent severe complications, and patients should be encouraged to adopt behavioral measures that reduce risk. Diagnosis is made through clinical and histopathological correlation. Currently, there is no curative treatment for PXE. However, advances in the underlying molecular pathways open the possibility for the development of novel therapeutic strategies, which may improve patient prognosis and potentially modify the natural history of the disease. Author Contributions Emilio Peniche‐Luna: conceptualization, formal analysis, investigation, resources, writing – original draft. Karen Uriarte‐Ruiz: conceptualization, investigation, writing – review and editing. José Eduardo Pérez‐Nieto: investigation, methodology, resources. Genaro Briseño‐Gascón: investigation, methodology, writing – original draft, writing – review and editing. María Elisa Vega‐Memije: conceptualization, investigation, supervision, validation, writing – review and editing. Simón Guzmán‐Bucio: conceptualization, formal analysis, investigation, resources, validation, writing – review and editing. Funding The authors have nothing to report. Consent Written informed consent from the patient was obtained according to journal guidelines. Conflicts of Interest The authors declare no conflicts of interest.